Key Points
- Director David Wells bought 48,400 shares of Hims & Hers Health for about $1.17 million at an average price of $24.23 per share, boosting his ownership by 27.5% to 224,417 shares.
- The company recently reported a larger-than-expected loss, with quarterly EPS of ($0.40) versus analyst estimates of $0.04, while revenue came in slightly below forecasts at $608.1 million.
- Analyst sentiment remains cautious, with the stock carrying a consensus Hold rating and an average price target of $28.70, after several firms trimmed targets or downgraded shares.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) Director David Wells acquired 48,400 shares of the firm's stock in a transaction on Tuesday, May 26th. The stock was purchased at an average cost of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares in the company, valued at approximately $5,437,623.91. This represents a 27.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Hims & Hers Health Stock Performance
Shares of NYSE HIMS opened at $23.79 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The stock's fifty day moving average price is $24.01 and its two-hundred day moving average price is $27.71. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of -264.33, a P/E/G ratio of 46.09 and a beta of 2.43.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 earnings per share. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on HIMS shares. Bank of America cut their target price on Hims & Hers Health from $28.00 to $25.00 and set a "neutral" rating for the company in a research report on Tuesday. JPMorgan Chase & Co. cut their target price on Hims & Hers Health from $35.00 to $33.00 and set an "overweight" rating for the company in a research report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a $25.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 5th. UBS Group set a $23.00 target price on Hims & Hers Health in a research report on Friday. Finally, Weiss Ratings downgraded Hims & Hers Health from a "hold (c)" rating to a "sell (d)" rating in a research report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and an average price target of $28.70.
Read Our Latest Report on HIMS
Institutional Trading of Hims & Hers Health
Several institutional investors and hedge funds have recently modified their holdings of HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock worth $12,373,000 after buying an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health in the first quarter valued at about $30,000. EverSource Wealth Advisors LLC raised its position in Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock valued at $47,000 after purchasing an additional 687 shares during the last quarter. Amundi raised its position in Hims & Hers Health by 5.3% in the second quarter. Amundi now owns 10,296 shares of the company's stock valued at $489,000 after purchasing an additional 522 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Hims & Hers Health by 9.5% in the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company's stock valued at $16,880,000 after purchasing an additional 29,471 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
